ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1788

Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE

Andrew Kwan1, Joan Wither2, Juan Pablo Diaz-Martinez2, Robin Green3, Dorcas Beaton4, Mahta Kakvan2, Lesley Ruttan3, Carmela Tartaglia5, Marvin Fritzler6, May Choi7, Jiandong Su2, Dennisse Bonilla2, Nicole Anderson2, Patricia Katz8 and Zahi Touma9, 1University of Toronto, Department of Medicine, Toronto, ON, Canada, 2University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 3Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, 4Institute for Work & Health, Toronto, ON, Canada, 5University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, 6Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 7Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 8University of California, San Francisco, Novato, CA, 9University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Cognitive dysfunction, informatics, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Cognitive impairment (CI) is among the earliest and the most prevalent manifestations of SLE. Previous studies have demonstrated that the increased levels of interferon (IFN)-induced gene expression in SLE are positively correlated with SLE disease activity and severity. The aim of this study is to examine the relationship between IFN levels and cognition as measured by the American College of Rheumatology neuropsychological battery (ACR-NB).

Methods: 301 consecutive consenting SLE patients (18 – 65 years old) attending a single center between Aug 2017 and Jan 2019 were enrolled in the study. IFN-induced gene expression was quantified by nanoString on RNA isolated from whole peripheral blood archive in TEMPUS tubes.  The log2 transformed normalized levels of five IFN-induced genes were summed to produce the IFN5 score. Cognition was measured using the ACR-NB (19 tests) representing manual dexterity, processing speed, language, simple attention, memory and executive function domains. Using age and gender stratified normative data, patients were classified on the ACR NB as having CI if a z-score of ≤-1.5 was observed in ≥ 2 domains or z ≤-2.0 in ≥1 domain. Principal Component Analysis (PCA) was used to explore the relationships among cognitive tests, interferon levels and SLE disease duration.

In PCA, the variance-covariance matrix of the cognitive tests was decomposed into a series of eigenvectors with corresponding eigenvalues. Each eigenvalue constitutes the variance of the linear combination of all test scores weighted by values contained in the corresponding eigenvector. This method reduces the dimensionality of the experimental data and to summarize the association between the variables in the data. To preserve the largest portion of the total variance explained by PCA, we only retained the first two components.

Moreover, we included IFN levels and SLE disease duration as supplementary variables.

Results: Of 301 patients, 89.0% were women,  mean age 40.9 ± 12.1 and mean disease duration 14 ± 10.1 years at study entry. PCA cognitive tests loaded onto 2 dimensions explained 39.6% of the variance in neuropsychological performance. The 1st  dimension (explained 28.3% of the total variance) was correlated mainly with more complex cognitive tests and primarily explained CI status of participants. The second dimension (11.3%) was mainly explained by measures of simple information processing or motor speed.

Fig 1a shows the patients’ component scores coloured by ACR-NB binary definition for CI and non-CI. This 1st dimension splits CI and non-CI patients at baseline. No clustering was observed when participants were categorized based on interferon level (Fig. 1b). No relationship was found between the cognitive tests and IFN levels or disease duration (Fig. 2). A weak negative correlation was also observed between interferon levels and RCFT and hand tapping, though this was not significant (Fig. 2).

Conclusion: This study assessed the relationship between IFN levels and cognitive function in patients with SLE. Using PCA analysis, we found no association between IFN levels and any cognitive tests, even after considering factors such as SLE disease duration.


Disclosure: A. Kwan, None; J. Wither, None; J. Diaz-Martinez, None; R. Green, None; D. Beaton, None; M. Kakvan, None; L. Ruttan, None; C. Tartaglia, None; M. Fritzler, Inova Diagnostics Inc, 5, 8, Werfen International, 5, 8; M. Choi, None; J. Su, None; D. Bonilla, None; N. Anderson, None; P. Katz, None; Z. Touma, None.

To cite this abstract in AMA style:

Kwan A, Wither J, Diaz-Martinez J, Green R, Beaton D, Kakvan M, Ruttan L, Tartaglia C, Fritzler M, Choi M, Su J, Bonilla D, Anderson N, Katz P, Touma Z. Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/assessment-of-the-impact-of-interferon-levels-on-cognitive-dysfunction-in-patients-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-the-impact-of-interferon-levels-on-cognitive-dysfunction-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology